Human ACOT7 activation kit by CRISPRa

CAT#: GA107799

ACOT7 CRISPRa kit - CRISPR gene activation of human acyl-CoA thioesterase 7



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
ACOT7 Antibody - C-terminal region
    • 100 ul

CNY 5,250.00


ACOT7 (Myc-DDK-tagged)-Human acyl-CoA thioesterase 7 (ACOT7), transcript variant hBACHd
    • 10 ug

CNY 2,400.00
CNY 3,990.00


ACOT7 rabbit polyclonal antibody
    • 25 ul

CNY 800.00
CNY 1,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol ACOT7
Locus ID 11332
Kit Components

GA107799G1, ACOT7 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA107799G2, ACOT7 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA107799G3, ACOT7 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_007274, NM_181862, NM_181863, NM_181864, NM_181865, NM_181866
Synonyms ACH1; ACT; BACH; CTE-II; hBACH; LACH; LACH1
Summary This gene encodes a member of the acyl coenzyme family. The encoded protein hydrolyzes the CoA thioester of palmitoyl-CoA and other long-chain fatty acids. Decreased expression of this gene may be associated with mesial temporal lobe epilepsy. Alternatively spliced transcript variants encoding distinct isoforms with different subcellular locations have been characterized. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...